Cost-utility analysis of add-on vericiguat for the treatment of chronic heart failure with reduced ejection fraction in China

• المؤلفون الرئيسيون: Lu Wang (مؤلف), Xuechen Huo (مؤلف), Haiyan Sun (مؤلف), Feiyu Liu (مؤلف), Ruiqin Huang (مؤلف), Quan Zhao (مؤلف)
• التنسيق: كتاب
• منشور في: BMC, 2024-05-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Abstract Objective This study aimed to evaluate the cost-utility of the addition of vericiguat for treating chronic heart failure (CHF) in China from the healthcare payer's perspective. Methods A Markov model was built to estimate the cost and utility of treating CHF using vericiguat plus stand...